Clinical trials: Chronic Heart Disease
Heart Failure, Congestive Heart Failure
Continued Access Protocol for the Evaluation of the OPTIMIZER Smart System
This is a multicenter, prospective, single-arm Continued Access study of the Optimizer Smart System with CCM therapy.
- Conditions
- Heart Failure, Congestive Heart Failure, Chronic Heart Disease, CHF
- Trial name
- FIX-HF-5CA (NCT03102437)
- Testing
- Optimizer Smart System
- Where
- 17 sites in United States
- Volunteers
- 106 people
- Sponsor
- Impulse Dynamics
Heart Failure
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY1067197) when given in addition to appropriate therapy for specific comorbidities.
- Trial name
- PANACHE (NCT03098979)
- Testing
- Neladenoson bialanate (BAY1067197)
- Where
- 76 sites in United States, Austria and 10 more
- Volunteers
- 305 people
- Sponsor
- Bayer
Heart Failure
Furosemide Pharmacodynamics and Pharmacokinetics After Subcutaneous or Oral Administration
The purpose of this pilot study is to investigate the pharmacodynamic and pharmacokinetic parameters of a novel furosemide formulation administered subcutaneously as compared to oral furosemide.
- Trial name
- FUROPHARM-HF (NCT02350725)
- Testing
- Furosemide injection solution for subcutaneous administration (80 mg), Oral Furosemide tablets (80 mg)
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- scPharmaceuticals, Inc.
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Hungary Satellite Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES)
- Trial name
- NCT01892917
- Where
- 13 sites in Hungary
- Volunteers
- 2,000 people
- Sponsor
- Biotronik Hungária Kft.
Kidney Disease, Chronic
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study.
- Trial name
- NCT06531824
- Testing
- BI 690517, Empagliflozin
- Where
- 562 sites in United States, Argentina and 18 more
- Volunteers
- 8,371 people
- Sponsor
- Boehringer Ingelheim
Chronic Kidney Disease + Hyperkalaemia +/- Heart Failure
Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia
This non-interventional, Phase IV, exploratory, cross-over, randomised, single-blind, active comparator-controlled study has been designed to measure the palatability and preference of Lokelma® versus Veltassa® versus S/CPS in…
- Trial name
- APPETIZE (NCT04566653)
- Testing
- Calcium Polystyrene Sulphonate 15g/60 mL water, Lokelma® 5 g/45mL water, Lokelma® 10 g/45 mL water
- Where
- 18 sites in United States, Canada and 4 more
- Volunteers
- 147 people
- Sponsor
- AstraZeneca
Coronary Artery Diseases
BIOFLOW-III VIP Russia Registry Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). Along with it, an explanatory (hypothesis-finding) problem will be investigated, whether the patient's body…
- Trial name
- NCT02247492
- Where
- 7 sites in Russia
- Volunteers
- 200 people
- Sponsor
- Biotronik Russia
Hypertension, Chronic Heart Failure
Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453
The purpose of this study is to assess the tolerability of BIA 5-453 after six multiple rising dose regimens of BIA 5-453.
- Trial name
- NCT02840565
- Testing
- BIA 5-453
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Heart Failure
Efficacy and Safety of Jia Shen Tablets in Chronic Heart Failure
Evaluate the efficacy and safety of Jia Shen Tablets in patients with Chronic Heart Failure.
- Trial name
- NCT06669169
- Testing
- Low dose Jia Shen Tablet, High dose Jia Shen Tablet
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Heart Failure, Heart Failure With Reduced Ejection Fraction
Effectiveness of CRD-740 in Heart Failure
This is a study evaluating the effectiveness of CRD-740 in patients with either Heart Failure with Reduced Ejection Fraction (HFrEF) or Heart Failure with Preserved Ejection Fraction (HFpEF) after 12 weeks of treatment.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Cardiovascular Diseases
- Trial name
- CARDINAL-HF (NCT05409183)
- Testing
- CRD-740
- Where
- 34 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Pulmonary Hypertension
Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension
The purpose of this study is to determine the safety and maximum tolerated dose of inhaled NX1011 for the treatment of pulmonary arterial hypertension (PAH).
- Trial name
- NCT00323024
- Testing
- NX1011
- Where
- 6 sites in United States
- Volunteers
- 72 people
- Sponsor
- NITROX, LLC
Heart Failure, Congestive
ACCLAIM - Advanced Chronic Heart Failure CLinical Assessment of Immune Modulation Therapy
The purpose of this study is to test the safety and efficacy of the Celacade™ system in reducing the risk of mortality and cardiovascular hospitalizations in patients with chronic systolic heart failure.
- Trial name
- NCT00111969
- Testing
- Celacade™ system
- Volunteers
- 2,016 people
- Sponsor
- Vasogen
Angina Pectoris
Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina
The purpose of this study is to determine the anti-angina effect and dose response of T89, a 2-herb botanical drug product, in patients with chronic stable angina pectoris in the United States.
- Trial name
- T89 phase 2 (NCT00797953)
- Testing
- T89
- Where
- 15 sites in United States
- Volunteers
- 124 people
- Sponsor
- Tasly Pharmaceuticals, Inc.
Atherosclerosis
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or stroke) in people with coronary heart disease.
- Trial name
- STABILITY (NCT00799903)
- Testing
- Darapladib
- Where
- 650 sites in United States, Argentina and 37 more
- Volunteers
- 15,828 people
- Sponsor
- GlaxoSmithKline
Heart Failure
Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure
This is an international, multicentre, parallel-group, randomised, double-blind, placebo controlled, phase II study to evaluate the benefits and risks of using sodium zirconium cyclosilicate (ZS) to initiate and intensify renin…
- Trial name
- PRIORITIZE HF (NCT03532009)
- Testing
- Sodium Zirconium Cyclosilicate
- Where
- 76 sites in United States, Brazil and 7 more
- Volunteers
- 182 people
- Sponsor
- AstraZeneca
Coronary Artery Chronic Total Occlusion
Facilitated Antegrade Steering Technique in Chronic Total Occlusions (FAST-CTOs)
Prospective, non-randomized, multicenter study in subjects with coronary artery chronic total occlusions (CTOs). Published results of safety and effectiveness of conventional techniques will be used for comparison.
- Trial name
- FAST-CTOs (NCT00886899)
- Testing
- Recanalization of a coronary chronic total occlusion
- Where
- 16 sites in United States
- Volunteers
- 147 people
- Sponsor
- BridgePoint Medical
Heart Failure
Model 4195 Left Ventricular (LV) Lead Chronic Performance Study
Evaluate long-term performance of the 4195 LV Lead. This evaluation is based on the number of lead-related complications occuring during the study compared to the number of leads enrolled in the study.
- Trial name
- NCT00869921
- Where
- 67 sites in United States, Canada and 1 more
- Volunteers
- 1,322 people
- Sponsor
- Medtronic
Coronary Artery Disease
A Trial to Evaluate Efficacy of Heart-protecting Musk Pill
Title: A randomized, double-blind, multi-centered, placebo-controlled trial to examine effects of of Heart-protecting Musk Pill on clinical outcomes in patients with chronic stable coronary artery disease Objective: To examine…
- Trial name
- NCT01897805
- Testing
- Heart-protecting Musk Pill
- Where
- 98 sites in China
- Volunteers
- 2,700 people
- Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD
Cardiac Safety Study
- Trial name
- CARSAF (NCT01584505)
- Testing
- CHF1535 + CHF5992 dose 1 BID, CHF1535 + CHF5992 dose2 BID, CHF1535 daily dose
- Where
- 6 sites in Bulgaria, Germany and 4 more
- Volunteers
- 191 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Heart Failure
Investigating the Role of Impella 2.5 System in Acutely Decompensated Chronic Heart Failure Patients
The primary objective of this study is to assess safety and feasibility of IMPELLA 2.5 in Acute Decompensated Heart Failure patients.
- Trial name
- RELIEF I (NCT01185691)
- Testing
- Impella 2.5
- Volunteers
- 1 people
- Sponsor
- Abiomed Inc.